301 related articles for article (PubMed ID: 34918546)
1. Encorafenib plus binimetinib in patients with
Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
[TBL] [Abstract][Full Text] [Related]
2. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussain M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
J Clin Oncol; 2023 Jul; 41(21):3700-3711. PubMed ID: 37270692
[TBL] [Abstract][Full Text] [Related]
3. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
4. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
5. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
[TBL] [Abstract][Full Text] [Related]
6. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussein M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
Future Oncol; 2024 Feb; ():. PubMed ID: 38357801
[TBL] [Abstract][Full Text] [Related]
7. A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with
Sullivan RJ; Weber J; Patel S; Dummer R; Carlino MS; Tan DSW; Lebbé C; Siena S; Elez E; Wollenberg L; Pickard MD; Sandor V; Ascierto PA
Clin Cancer Res; 2020 Oct; 26(19):5102-5112. PubMed ID: 32669376
[TBL] [Abstract][Full Text] [Related]
8. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.
Dummer R; Flaherty KT; Robert C; Arance A; B de Groot JW; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; Pietro AD; Cantey-Kiser J; Edwards M; Ascierto PA
Future Oncol; 2023 May; 19(16):1091-1098. PubMed ID: 37309702
[TBL] [Abstract][Full Text] [Related]
9. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
[TBL] [Abstract][Full Text] [Related]
10. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
Trojaniello C; Festino L; Vanella V; Ascierto PA
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516
[TBL] [Abstract][Full Text] [Related]
11. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D; Besse B; Groen HJM; Souquet PJ; Quoix E; Baik CS; Barlesi F; Kim TM; Mazieres J; Novello S; Rigas JR; Upalawanna A; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2016 Jul; 17(7):984-993. PubMed ID: 27283860
[TBL] [Abstract][Full Text] [Related]
12. STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable
Schadendorf D; Dummer R; Robert C; Ribas A; Sullivan RJ; Panella T; McKean M; Santos ES; Brill K; Polli A; Pietro AD; Ascierto PA
Future Oncol; 2022 Jun; 18(17):2041-2051. PubMed ID: 35272485
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).
Gogas H; Dummer R; Ascierto PA; Arance A; Mandalà M; Liszkay G; Garbe C; Schadendorf D; Krajsová I; Gutzmer R; Sileni VC; Dutriaux C; Yamazaki N; Loquai C; Queirolo P; Jan de Willem G; Sellier AT; Suissa J; Murris J; Gollerkeri A; Robert C; Flaherty KT
Eur J Cancer; 2021 Jul; 152():116-128. PubMed ID: 34091420
[TBL] [Abstract][Full Text] [Related]
14. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With
Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; di Pietro A; Cantey-Kiser J; Edwards M; Ascierto PA
J Clin Oncol; 2022 Dec; 40(36):4178-4188. PubMed ID: 35862871
[TBL] [Abstract][Full Text] [Related]
15. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
Holbrook K; Lutzky J; Davies MA; Davis JM; Glitza IC; Amaria RN; Diab A; Patel SP; Amin A; Tawbi H
Cancer; 2020 Feb; 126(3):523-530. PubMed ID: 31658370
[TBL] [Abstract][Full Text] [Related]
16. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With
Van Cutsem E; Huijberts S; Grothey A; Yaeger R; Cuyle PJ; Elez E; Fakih M; Montagut C; Peeters M; Yoshino T; Wasan H; Desai J; Ciardiello F; Gollerkeri A; Christy-Bittel J; Maharry K; Sandor V; Schellens JHM; Kopetz S; Tabernero J
J Clin Oncol; 2019 Jun; 37(17):1460-1469. PubMed ID: 30892987
[TBL] [Abstract][Full Text] [Related]
17. A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Baik C; Cheng ML; Dietrich M; Gray JE; Karim NA
Adv Ther; 2024 May; ():. PubMed ID: 38698170
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients.
Indini A; Mandalà M
Expert Opin Drug Saf; 2020 Oct; 19(10):1229-1236. PubMed ID: 32857940
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report.
Gelsomino F; Di Federico A; Tardio ML; Grilli G; D'Errico A; Ardizzoni A; Salvagni S
Invest New Drugs; 2022 Feb; 40(1):190-193. PubMed ID: 34436699
[TBL] [Abstract][Full Text] [Related]
20. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma.
van Akkooi AC; Hauschild A; Long GV; Mandala M; Kicinski M; Govaerts AS; Klauck I; Ouali M; Lorigan PC; Eggermont AM
Future Oncol; 2023 Sep; 19(30):2017-2027. PubMed ID: 37665297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]